Skip to main content
Menu

Posts tagged with "Clinical Trials"

  • Clinical Trials

    Merck Keeps Plowing On

    I last wrote about the small-molecule antiviral molnupiravir here, and we finally have more information from Merck and Ridgeback about its effects in clinical trials. An interim analysis of the Phase II data from trials in both outpatients and in hospitalized coronavirus patients has been completed, and the news is. . .mixed. In the outpatient… Read More
  • Clinical Trials

    Oligonucleotides And Their Discontents

    I remember being at a chemistry meeting in New Jersey back in around 1990 or 1991, where a speaker mentioned in passing that most of the people in the room would probably soon be offered a chance to move to California and work for some small company trying to develop antisense drugs. There was a… Read More
  • Clinical Trials

    AstraZeneca’s US Vaccine Trial Data

    Update: this has turned into a stupid, needless, mess. Which frankly seems to be AstraZeneca’s pandemic brand so far. It turns out that the company’s press release (as discussed below) is apparently more of an interim read than reflective of the final data. The NIH took the extraordinary step of stating its concerns about this… Read More
  • AI and Machine Learning

    AI and Drug Discovery: Attacking the Right Problems

    I’ve been meaning to write some more about artificial intelligence, machine learning, and drug discovery, and this paper (open access) by Andreas Bender is an excellent starting point. I’m going to be talking in fairly general terms here, but for practitioners in the field, I can recommend this review of the 2020 literature by Pat Walt… Read More
  • Clinical Trials

    The Problem with COVID-19 Clinical Trials

    Let’s talk about a painful subject. I am of the opinion – and I’m far from alone – that the most reliable way to determine if a possible therapy has any usefulness is a randomized, double-blinded controlled clinical trial. I can be a bit more specific than that, even: let’s make that “a trial that… Read More
  • Alzheimer's Disease

    Lilly’s Alzheimer’s Data

    That’s a post title that I could have used eight or ten times over the lifetime of this blog – Eli Lilly has been hammering away at Alzheimer’s for a long time now. They have yet another anti-amyloid antibody study out this week, and (as has happened over and over in this area) it as… Read More
  • Cancer

    Androgen Receptors for COVID-19

    There’s a report of an interesting small-molecule drug effort against the coronavirus that seems to have produced rather significant results. The idea goes back to effects that were noticed last year – for example, in this population-based study from Italy. It’s been known since the early days of the pandemic that males were overa… Read More
  • Cancer

    Cancer and Gene Therapy

    Update, March 10: Bluebird has reported data that makes it much less likely that this even was due to their lentivirus vector. Good news, and I hope it holds up. There’s news today that Bluebird has suspended its gene therapy work on sickle cell disease because of two cases of cancer in its treatment population. Read More
  • Clinical Trials

    GLP-1 and Obesity

    Let’s have a look at a paper that came out recently in the New England Journal of Medicine. It shows strong results in a therapeutic area that a lot of people have spent a lot of effort on: obesity. I’ve been kicking around the idea of reviewing the history of anti-obesity drug discovery, but it’s… Read More
  • Clinical Trials

    The Oxford/AstraZeneca Vaccine Efficacy Data

    We now have a complete writeup of the efficacy data from the Oxford/AZ vaccine effort in The Lancet, and I’m glad to see it. There have been a number of questions about this candidate and its effects in the clinic, so the chance to get a closer look is welcome. This is of course the… Read More